IM-4320 / Immunome - LARVOL DELTA

Immunome Reports Third Quarter 2023 Financial Results (Businesswire) - "Highlights: (i) IMM-ONC-01: We expect to provide guidance in Q1 2024 regarding our timeline to submit to the FDA an IND for IMM-ONC-01; (ii) 177Lu-FAP: We anticipate an IND submission with the FDA in Q1 2025."

IND • Oncology

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies (Businesswire) - "Immunome...and Morphimmune...today announced that they have entered into a definitive merger agreement...The companies also announced an oversubscribed private placement investment of $125 million....The investment will be used to continue development of the lead assets in Immunome’s combined pipeline, to continue to advance the company’s platforms, and for general working capital purposes. The combined pipeline includes a novel anti-IL-38 mAb derived from Immunome’s discovery engine, as well as a folate receptor-targeted TLR7 agonist (FA-TLR7a) and FAP-targeted radioligand (177Lu-FAP). The company expects to submit three INDs within 18 months following the closing, including the anti-IL-38 program, which is now slated for submission in Q1 2024."

IND • M&A • Gastroesophageal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation. (PubMed, MAbs) - "Together, our data suggest that IL-38 is expressed in a high frequency of cancer patients and allows tumor cells to suppress anti-tumor immunity. Blockade of IL-38 activity using IMM20324 can re-activate immunostimulatory mechanisms in the tumor microenvironment leading to immune infiltration, the generation of tumor-specific memory and abrogation of tumor growth."

IO biomarker • Journal • Breast Cancer • Cervical Cancer • Immune Modulation • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • IL1RAP

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity (Businesswire) - "Immunome...announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled 'IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,' in the peer-reviewed journal mAbs....An anti-IL-38 antibody, identified by Immunome, inhibits tumor growth in two in-vivo preclinical cancer models. Treatment in these models with the IL-38 blocking antibody resulted in increased levels of intra-tumoral chemokines."

Preclinical • Oncology • Solid Tumor

Immunome Reports Third Quarter 2022 Financial Results (Businesswire) - "Immunome, Inc...reported financial results for the third quarter ended September 30, 2022 and provided a corporate update...'We look forward to completing our clinical trial for IMM-BCP-01, our COVID-19 antibody program, while continuing to expand our oncology portfolio including our planned submission of the IND for IMM-ONC-01 by mid-2023.'...R&D expenses for the three months ended September 30, 2022, were $5.2 million."

Commercial • IND • Oncology • Solid Tumor

Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 (Businesswire) - "Immunome...announced updates to the ongoing development of its lead oncology program, IMM-ONC-01....Preclinical research conducted by Immunome, and literature evidence1,2, suggests IL-38 dampens natural anti-tumor immune response. In animal testing, blocking IL-38 activity using Immunome’s antibody produced an anti-tumor effect.....Profiling of IL-38 mRNA in over 60 cancer types revealed notably high frequency (60-80%) of IL-38 expression in select solid tumor sub-types of high unmet clinical need....'We are on track to file an IND later in 2022'..."

IND • Preclinical • Basal Cell Carcinoma • Gastroesophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer

Immunome Reports Third Quarter 2021 Financial Results (Businesswire) - "...'We continue to advance IMM-ONC-01, our novel innate immune checkpoint that targets IL-38, towards an IND submission that we expect in early 2022'."

IND • Oncology

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire) - "The presentation highlighted that Immunome’s antibody:...Binds to human IL-38 and inhibits binding to its putative receptors, IL1RAPL1 and IL-36R; Inhibits IL-38-mediated suppression of myeloid cell activity in vitro."

Preclinical • Oncology • Solid Tumor

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire) - "Immunome...announced that it will be making an oral poster presentation on the company’s anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021."

Preclinical • Oncology

[VIRTUAL] IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo (AACR-NCI-EORTC 2021) - No abstract available

Late-breaking abstract • Preclinical • Oncology

Immunome Reports Second Quarter 2021 Financial Results (Businesswire) - "...'We have continued to strengthen the company through a number of executive and non-executive appointments, in addition to a successful fundraising. We believe these activities set us up for value-creating events in the near-term, including a planned IND filing for our IL-38 immuno-oncology program in the fourth quarter'."

IND • Oncology